English
Despite remarkable progress in the past two decades in preventing myocardial infarction and stroke, the thrombotic complications of the atherosclerotic process are still a leading cause of morbidity and mortality. The demonstration that streptokinase, a thrombolytic agent, and low-dose aspirin, an antiplatelet agent, can each reduce mortality from vascular causes by about one quarter when administered early in the course of an acute myocardial infarction, and that their separate benefits are additive when the two drugs are given together, has dramatically changed the life expectancy of patients with myocardial infarction and provides compelling evidence that coronary thrombosis is a dynamic, modifiable process.
| Shipping Cost |
|
| Delivery Time | Ready to ship in 3-5 Business Days |
| Shop Location | Cairo, مصر |
No reviews found!
No comments found for this product. Be the first to comment!